{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:14:35Z","timestamp":1753892075736,"version":"3.41.2"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,6,8]],"date-time":"2018-06-08T00:00:00Z","timestamp":1528416000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2018.00608","type":"journal-article","created":{"date-parts":[[2018,6,8]],"date-time":"2018-06-08T13:40:21Z","timestamp":1528465221000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Long-Term Intravitreal Ranibizumab as a Potential Additional Risk Factor for Neurodegeneration in Parkinson\u2019s Disease: A Case Report"],"prefix":"10.3389","volume":"9","author":[{"given":"Gianluca","family":"Trifir\u00f2","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Marcian\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola M.","family":"Cutroneo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edoardo","family":"Spina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliana","family":"Mirabelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Costantino J.","family":"Trombetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Morgante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2018,6,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.parkreldis.2012.03.017","article-title":"The relationship between cerebral vascular disease and parkinsonism: the VADO study.","volume":"18","author":"Antonini","year":"2012","journal-title":"Parkinsonism Relat. Disord."},{"key":"B2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/mds.25741","article-title":"Venturing into the no-man\u2019s land of the retina in Parkinson\u2019s disease.","volume":"29","author":"Bodis-Wollner","year":"2014","journal-title":"Mov. Disord."},{"key":"B3","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.amjmed.2015.10.015","article-title":"Mining retrospective data for virtual prospective drug repurposing: L-DOPA and age-related macular degeneration.","volume":"129","author":"Brilliant","year":"2016","journal-title":"Am. J. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration.","volume":"355","author":"Brown","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"464.e1","DOI":"10.1016\/j.ajo.2013.09.026","article-title":"Increased risk of Parkinson disease following a diagnosis of neovascular age-related macular degeneration: a retrospective cohort study.","volume":"157","author":"Chung","year":"2014","journal-title":"Am. J. Ophthalmol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s40264-017-0553-y","article-title":"Overview of the safety of anti-VEGF drugs: analysis of the italian spontaneous reporting system.","volume":"40","author":"Cutroneo","year":"2017","journal-title":"Drug Saf."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1056\/NEJMra062326","article-title":"Age-related macular degeneration.","volume":"355","author":"de Jong","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2008.10.001","article-title":"Molecular pathology of age-related macular degeneration.","volume":"28","author":"Ding","year":"2009","journal-title":"Prog. Retin. Eye Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"7657","DOI":"10.1073\/pnas.92.17.7657","article-title":"Exogenous vascular endothelial growth factor induces malformed and hyperfused vessels during embryonic neovascularization.","volume":"92","author":"Drake","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B10","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1097\/IAE.0000000000000320","article-title":"Long-term alterations of systemic vascular endothelial growth factor levels in patients treated with ranibizumab for age-related macular degeneration.","volume":"35","author":"Enders","year":"2015","journal-title":"Retina"},{"key":"B11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.neulet.2011.03.088","article-title":"Vascular endothelial growth factor-B is neuroprotective in an in vivo rat model of Parkinson\u2019s disease.","volume":"496","author":"Falk","year":"2011","journal-title":"Neurosci. Lett."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1517\/14740338.2014.939951","article-title":"A safety evaluation of ranibizumab in the treatment of age-related macular degeneration.","volume":"13","author":"Gibson","year":"2014","journal-title":"Expert Opin. Drug Saf."},{"key":"B13","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1097\/IAE.0b013e318276e07b","article-title":"Myocardial infarction after intravitreal vascular endothelial growth factor inhibitors: a whole population study.","volume":"33","author":"Kemp","year":"2013","journal-title":"Retina"},{"key":"B14","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.expneurol.2008.03.019","article-title":"Roles of the endogenous VEGF receptors flt-1 and flk-1 in astroglial and vascular remodeling after brain injury.","volume":"212","author":"Krum","year":"2008","journal-title":"Exp. Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/bpa.12130","article-title":"Reduced vascular endothelial growth factor and capillary density in the occipital cortex in dementia with Lewy bodies.","volume":"24","author":"Miners","year":"2014","journal-title":"Brain Pathol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions.","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin. Pharmacol. Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.12659\/MSM.890861","article-title":"Ophthalmological features of Parkinson disease.","volume":"20","author":"Nowacka","year":"2014","journal-title":"Med. Sci. Monit."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.npep.2011.05.005","article-title":"Vascular endothelial growth factor (VEGF) and its role in the central nervous system: a new element in the neurotrophic hypothesis of antidepressant drug action.","volume":"46","author":"Nowacka","year":"2012","journal-title":"Neuropeptides"},{"key":"B19","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.neuroscience.2011.06.084","article-title":"Vascular endothelial growth factor C acts as a neurotrophic factor for dopamine neurons in vitro and in vivo.","volume":"192","author":"Piltonen","year":"2011","journal-title":"Neuroscience"},{"key":"B20","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S0014-4886(03)00100-6","article-title":"Angiogenic and neurotrophic effects of vascular endothelial growth factor (VEGF165): studies of grafted and cultured embryonic ventral mesencephalic cells.","volume":"182","author":"Pitzer","year":"2003","journal-title":"Exp. Neurol."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease.","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson\u2019s disease.","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov. Disord."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s40264-014-0231-2","article-title":"Ranibizumab and risk of hospitalisation for ischaemic stroke and myocardial infarction in patients with age-related macular degeneration: a self-controlled case-series analysis.","volume":"37","author":"Pratt","year":"2014","journal-title":"Drug. Saf."},{"key":"B24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.actbio.2014.12.017","article-title":"Effects of mesenchymal stem cell therapy, in association with pharmacologically active microcarriers releasing VEGF, in an ischaemic stroke model in the rat.","volume":"15","author":"Quittet","year":"2015","journal-title":"Acta Biomater."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration.","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2165\/11597600-000000000-00000","article-title":"Novel adverse events of bevacizumab in the US FDA adverse event reporting system database: a disproportionality analysis.","volume":"35","author":"Shamloo","year":"2012","journal-title":"Drug Saf."},{"key":"B27","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.actbio.2016.12.048","article-title":"Polylysine-modified polyethylenimine (PEI-PLL) mediated VEGF gene delivery protects dopaminergic neurons in cell culture and in rat models of Parkinson\u2019s Disease (PD).","volume":"54","author":"Sheikh","year":"2017","journal-title":"Acta Biomater."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1016\/S0306-4522(98)00540-5","article-title":"Vascular, glial and neuronal effects of vascular endothelial growth factor in mesencephalic explant cultures.","volume":"90","author":"Silverman","year":"1999","journal-title":"Neuroscience"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1002\/mds.26411","article-title":"A novel retinal biomarker for Parkinson\u2019s disease: quantifying the foveal pit with optical coherence tomography.","volume":"30","author":"Slotnick","year":"2015","journal-title":"Mov. Disord."},{"key":"B30","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.mayocp.2011.10.001","article-title":"The expanding role of vascular endothelial growth factor inhibitors in ophthalmology.","volume":"87","author":"Stewart","year":"2012","journal-title":"Mayo Clin. Proc."},{"key":"B31","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1172\/JCI20682","article-title":"VEGF: a critical player in neurodegeneration.","volume":"113","author":"Storkebaum","year":"2004","journal-title":"J. Clin. Invest."},{"key":"B32","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.neulet.2007.05.033","article-title":"Favorable effects of VEGF gene transfer on a rat model of Parkinson disease using adeno-associated viral vectors.","volume":"421","author":"Tian","year":"2007","journal-title":"Neurosci. Lett."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2016.00020","article-title":"Brain and retinal pericytes: origin, function and role.","volume":"2016","author":"Trost","year":"2016","journal-title":"Front. Cell. Neurosci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1016\/j.ophtha.2014.05.022","article-title":"Systemic vascular safety of ranibizumab for age-related macular degeneration: systematic review and meta-analysis of randomized trials.","volume":"121","author":"Ueta","year":"2014","journal-title":"Ophthalmology"},{"key":"B35","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/sj.bjp.0707167","article-title":"Inflammation as a causative factor in the aetiology of Parkinson\u2019s disease.","volume":"150","author":"Whitton","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s10072-016-2691-x","article-title":"Association of VEGF gene polymorphisms with sporadic Parkinson\u2019s disease in Chinese Han population.","volume":"37","author":"Wu","year":"2016","journal-title":"Neurol. Sci."},{"key":"B37","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.expneurol.2007.05.012","article-title":"Correlation between levels of pigment epithelium-derived factor and vascular endothelial growth factor in the striatum of patients with Parkinson\u2019s disease.","volume":"206","author":"Yasuda","year":"2007","journal-title":"Exp. Neurol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1111\/j.1460-9568.2004.03254.x","article-title":"Neuroprotective effects of vascular endothelial growth factor (VEGF) upon dopaminergic neurons in a rat model of Parkinson\u2019s disease.","volume":"19","author":"Yasuhara","year":"2004","journal-title":"Eur. J. Neurosci."},{"key":"B39","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.brainres.2005.05.027","article-title":"Neurorescue effects of VEGF on a rat model of Parkinson\u2019s disease.","volume":"1053","author":"Yasuhara","year":"","journal-title":"Brain Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.brainres.2004.12.055","article-title":"The differences between high and low-dose administration of VEGF to dopaminergic neurons of in vitro and in vivo Parkinson\u2019s disease model.","volume":"1038","author":"Yasuhara","year":"","journal-title":"Brain Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.jacc.2006.09.053","article-title":"Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine.","volume":"49","author":"Yla-Herttuala","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.neuroscience.2013.11.038","article-title":"Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson\u2019s disease.","volume":"258","author":"Yue","year":"2014","journal-title":"Neuroscience"},{"key":"B43","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1159\/000088637","article-title":"Neuroprotective role of vascular endothelial growth factor: signalling mechanisms, biological function, and therapeutic potential.","volume":"14","author":"Zachary","year":"2005","journal-title":"Neurosignals"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e154","DOI":"10.1111\/aos.12604","article-title":"Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.","volume":"93","author":"Zehetner","year":"2015","journal-title":"Acta Ophthalmol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2018.00608\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,6,8]],"date-time":"2018-06-08T13:40:22Z","timestamp":1528465222000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2018.00608\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,8]]},"references-count":44,"alternative-id":["10.3389\/fphar.2018.00608"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2018.00608","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2018,6,8]]},"article-number":"608"}}